These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29269345)

  • 1. PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
    Cancer Discov; 2018 Feb; 8(2):136. PubMed ID: 29269345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
    Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
    J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
    Doherty GJ; Tempero M; Corrie PG
    Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
    Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
    Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Gemcitabine Delivery by
    Russell J; Grkovski M; O'Donoghue IJ; Kalidindi TM; Pillarsetty N; Burnazi EM; Kulick A; Bahr A; Chang Q; LeKaye HC; de Stanchina E; Yu KH; Humm JL
    J Nucl Med; 2021 Feb; 62(2):195-200. PubMed ID: 32646874
    [No Abstract]   [Full Text] [Related]  

  • 7. [Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
    Kim DU
    Korean J Gastroenterol; 2018 Apr; 71(4):244-245. PubMed ID: 29684975
    [No Abstract]   [Full Text] [Related]  

  • 8. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
    Gourd E
    Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
    [No Abstract]   [Full Text] [Related]  

  • 10. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metastatic pancreatic adenocarcinoma: a review.
    Thota R; Pauff JM; Berlin JD
    Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
    John P; Butler H; Saif MW
    Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
    Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
    Vivaldi C; Fornaro L; Caparello C; Falcone A; Vasile E
    Br J Cancer; 2016 May; 114(11):e8. PubMed ID: 27124336
    [No Abstract]   [Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
    Pernot S; Bachet JB; Portal A; Taieb J
    Br J Cancer; 2016 May; 114(11):e9. PubMed ID: 27124338
    [No Abstract]   [Full Text] [Related]  

  • 20. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.